share_log

AbbVie | 8-K: Guidance Including the Impact of Acquired IPR&D and Milestones Expense (Unaudited)

AbbVie | 8-K: Guidance Including the Impact of Acquired IPR&D and Milestones Expense (Unaudited)

艾伯維公司 | 8-K:艾伯維公司指導方針包括收購的知識產權研發及里程碑費用的影響
美股SEC公告 ·  10/03 16:12

Moomoo AI 已提取核心訊息

AbbVie Inc. has released preliminary financial results for the third quarter of 2024, including the impact of acquired IPR&D and milestones expense. The company reported an expense of $82 million on a pre-tax basis, which is expected to negatively affect both GAAP and non-GAAP diluted earnings per share by $0.04. AbbVie's third quarter results have not been finalized and are subject to financial statement closing procedures. The company's full-year 2024 adjusted diluted earnings per share guidance, including the third quarter expense, is projected to be between $10.67 and $10.87. The third quarter adjusted diluted earnings per share guidance is estimated to be between $2.88 and $2.92, reflecting the incurred expense. AbbVie has previously announced that its adjusted diluted earnings per share guidance for 2024 would exclude the impact of any acquired IPR&D and milestones expense beyond the second quarter. The company cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied.
AbbVie Inc. has released preliminary financial results for the third quarter of 2024, including the impact of acquired IPR&D and milestones expense. The company reported an expense of $82 million on a pre-tax basis, which is expected to negatively affect both GAAP and non-GAAP diluted earnings per share by $0.04. AbbVie's third quarter results have not been finalized and are subject to financial statement closing procedures. The company's full-year 2024 adjusted diluted earnings per share guidance, including the third quarter expense, is projected to be between $10.67 and $10.87. The third quarter adjusted diluted earnings per share guidance is estimated to be between $2.88 and $2.92, reflecting the incurred expense. AbbVie has previously announced that its adjusted diluted earnings per share guidance for 2024 would exclude the impact of any acquired IPR&D and milestones expense beyond the second quarter. The company cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied.
艾伯維公司已發佈2024年第三季度初步財務業績,包括已收購的研發和里程碑費用的影響。該公司報告了稅前8,200萬美元的支出,預計將對按美國通用會計準則(GAAP)和非通用會計準則(non-GAAP)計算的稀釋每股收益均造成0.04美元的負面影響。艾伯維公司的第三季度業績尚未最終確定,並受財務報表結賬程序的影響。包括第三季度支出在內的艾伯維公司2024年調整後每股稀釋收益指導範圍預計爲10.67至10.87美元。第三季度調整後每股稀釋收益指導範圍預計爲2.88至2.92美元,反映了已發生的支出。艾伯維公司此前宣佈,其2024年調整後每股稀釋收益指導將不包括第二季度之後已收購的研發和里程碑費用的影響。該公司警告稱,這些前瞻性聲明受到可能導致實際結果與預期結果有重大不同的風險和不確定性影響。
艾伯維公司已發佈2024年第三季度初步財務業績,包括已收購的研發和里程碑費用的影響。該公司報告了稅前8,200萬美元的支出,預計將對按美國通用會計準則(GAAP)和非通用會計準則(non-GAAP)計算的稀釋每股收益均造成0.04美元的負面影響。艾伯維公司的第三季度業績尚未最終確定,並受財務報表結賬程序的影響。包括第三季度支出在內的艾伯維公司2024年調整後每股稀釋收益指導範圍預計爲10.67至10.87美元。第三季度調整後每股稀釋收益指導範圍預計爲2.88至2.92美元,反映了已發生的支出。艾伯維公司此前宣佈,其2024年調整後每股稀釋收益指導將不包括第二季度之後已收購的研發和里程碑費用的影響。該公司警告稱,這些前瞻性聲明受到可能導致實際結果與預期結果有重大不同的風險和不確定性影響。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息